3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
50
Prostatic Neoplasms
23
Lung Neoplasms
17
Breast Neoplasms
16
Squamous Cell Carcinoma of Head and Neck
13
Neoplasms
9
Stomach Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Neoplasm Metastasis
6
Head and Neck Neoplasms
6
Carcinoma, Transitional Cell
6
Urinary Bladder Neoplasms
5
Triple Negative Breast Neoplasms
5
Non-Muscle Invasive Bladder Neoplasms
5
Endometrial Neoplasms
5
Carcinoma, Squamous Cell
5
Prostatic Neoplasms, Castration-Resistant
4
Oropharyngeal Neoplasms
4
Small Cell Lung Carcinoma
3
Salivary Gland Neoplasms
3
Ovarian Neoplasms
3
Nasopharyngeal Carcinoma
3
HER2-positive Breast Cancer
3
Esophageal Squamous Cell Carcinoma
3
Carcinoma
3
Anatomic Stage I Breast Cancer AJCC v8
3
Adenocarcinoma
3
Vaccinia
2
Solid Tumors
2
Sarcoma
2
Interventions
Paclitaxel
6
Mitomycin
3
Carboplatin
3
Bevacizumab
3
sodium thiosulfate
2
Laparoscopy
2
Hyperthermic Intraperitoneal Chemotherapy
2
Cisplatin
2
relacorilant
1
pembrolizumab
1
oregovomab
1
olaparib
1
nilotinib
1
liposomal doxorubicin
1
Topotecan
1
Taxes
1
Standard of Care
1
Specimen Handling
1
Saline Solution
1
Practice Guidelines as Topic
1
Pancreatectomy
1
Oxaliplatin
1
Magnetic Resonance Spectroscopy
1
Laparotomy
1
Glucose
1
Gemcitabine
1
Fluorouracil
1
Electrocardiography
1
Doxorubicin
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Peritoneal Neoplasms
×
Docetaxel
×
90 days
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts